Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Mycobacterium tuberculosis (M. tb), also known as Koch's bacillus, is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis. [ 1 ] [ 2 ] First discovered in 1882 by Robert Koch , M. tuberculosis has an unusual, waxy coating on its cell surface primarily due to the presence of mycolic acid .
In 2018, one quarter of the world's population was thought to have a latent infection of TB. [6] New infections occur in about 1% of the population each year. [11] In 2022, an estimated 10.6 million people developed active TB, resulting in 1.3 million deaths, making it the second leading cause of death from an infectious disease after COVID-19. [1]
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
Treatment of MDR-TB requires treatment with second-line drugs, usually four or more anti-TB drugs for a minimum of 6 months, and possibly extending for 18–24 months if rifampin resistance has been identified in the specific strain of TB with which the patient has been infected. [9] Under ideal program conditions, MDR-TB cure rates can ...
Prospects for tuberculosis control and elimination in a hypothetical high-burden country, starting in 2015. Tuberculosis has been a curable illness since the 1940s when the first drugs became available, although multidrug-resistant and extensively drug-resistant TB present an increasing challenge. [5]
The true scale of XDR-TB is unknown as many countries lack the necessary equipment and capacity to accurately diagnose it. By June 2008, 49 countries had confirmed cases of XDR-TB. [3] By the end of 2017, 127 WHO Member States reported a total of 10,800 cases of XDR-TB, and 8.5% of cases of MDR-TB in 2017 were estimated to have been XDR-TB. [2]
In tuberculosis-endemic regions, tuberculous pericarditis accounts for 50-90% of cases of effusive pericarditis, depending on HIV status. [6] In developed countries, it only accounts for about 4% of cases. [6] Tuberculous pericarditis is a deadly disease with a mortality rate of up to 40% in the first 6 months after diagnosis. [6]